Compare AMBO & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBO | AIDX |
|---|---|---|
| Founded | 2000 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Precision Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 4.9M |
| IPO Year | 2010 | 2025 |
| Metric | AMBO | AIDX |
|---|---|---|
| Price | $1.84 | $0.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.9K | ★ 57.4K |
| Earning Date | 11-11-2026 | 11-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 337.04 | 34.48 |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $9,469,000.00 | $2,045,133.00 |
| Revenue This Year | N/A | $44.20 |
| Revenue Next Year | N/A | $95.73 |
| P/E Ratio | $377.55 | ★ N/A |
| Revenue Growth | 0.82 | ★ 16.71 |
| 52 Week Low | $1.47 | $0.33 |
| 52 Week High | $5.40 | $18.96 |
| Indicator | AMBO | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 35.97 | 34.08 |
| Support Level | $1.69 | $0.33 |
| Resistance Level | $2.19 | $0.49 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 7.04 | 18.51 |
Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.